Chromenopyrazole Derivatives for Selective GPR55 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for GPR55-related diseases lack effective GPR55 receptor-specific agonists and antagonists, limiting therapeutic options for conditions such as diabetes, Parkinson's disease, multiple sclerosis, and various cancers.
Innovation Solution
Development of novel chromenopyrazole-based compounds that selectively modulate the GPR55 receptor, acting as both pharmacological tools and therapeutic agents for treating GPR55-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GPR55 receptor-specific agonists and antagonists are developed, then therapeutic options for GPR55-related diseases are improved, but currently no such specific compounds exist limiting treatment effectiveness
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of chromenopyrazole compounds (formula I) through varying substituents R1, R2, and R3 to optimize GPR55 receptor binding affinity and selectivity. This structural parameter optimization enables the development of compounds with enhanced therapeutic effectiveness for GPR55-related diseases while maintaining selectivity against CB1 and CB2 receptors.
2Reliability
If chromenopyrazole-based compounds are designed to selectively modulate GPR55, then therapeutic benefits for GPR55-related disorders are achieved, but selectivity against CB1 and CB2 cannabinoid receptors must be maintained
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at defined positions (R1, R2, R3) on the chromenopyrazole core structure to create localized interactions with the GPR55 receptor binding site. These localized structural modifications enable selective binding to GPR55 while preventing interaction with CB1 and CB2 receptors, achieving selectivity without requiring complete structural redesign.
Solution Approach 2:
The patent employs asymmetry by designing compounds with non-symmetric substituent patterns on the chromenopyrazole scaffold, creating a three-dimensional molecular shape that complements the asymmetric binding pocket of the GPR55 receptor. This asymmetric design enhances selectivity by ensuring steric compatibility with GPR55 while creating steric clashes with the binding sites of CB1 and CB2 receptors.
Data Source
Figure 1
Figure 1
Figure 1
AI summary
The present invention relates to a family of chromenopyrazole derivatives of formula (I): which have the ability to modulate the receptor of the cannabinoid family GPR55, whereby the invention also relates to the use of these compounds for the manufacture of a medicament for the treatment of diseases in which the GPR55 receptor has a physiological role such as diabetes, Parkinson's disease, multiple sclerosis, neuropathic pain, osteoporosis and cancers such as cholangiocarcinoma, breast cancer, ovarian and prostate cancer, glioblastoma, and cutaneous carcinoma.